PMLiVE9d
AbbVie shares promising late-stage results for Parkinson’s disease candidate tavapadon
AbbVie has shared positive top-line results from a late-stage study of its investigational Parkinson’s disease (PD) drug in ...
PMLiVE13d
Top-10 ways for Pharma to leverage AI according to…AI
Like most people these days, I have been experimenting with various artificial intelligence (AI) tools this past year. It’s ...
PMLiVE6d
Merck’s Keytruda shows promise as perioperative head and neck cancer treatment
Keytruda works by increasing the ability of the body’s immune system to help detect and fight tumour cells, and is already approved as a monotherapy and in combination regimens for certain patients ...
PMLiVE7d
Merck and Mestag enter inflammatory disease partnership worth up to $1.9bn
Merck & Co – known as MSD outside the US and Canada – has entered into a licence and research collaboration agreement worth ...
PMLiVE8d
J&J’s Erleada shows overall survival benefit in head-to-head prostate cancer study
Johnson & Johnson (J&J) has announced results from a real-world study comparing its Erleada (apalutamide) to Pfizer and ...
PMLiVE10d
AstraZeneca gains rights to CSPC’s lipid-lowering therapy in deal worth over $1.9bn
AstraZeneca (AZ) has entered into an exclusive licence agreement worth over $1.9bn to advance CSPC Pharmaceutical Group’s pre-clinical lipid-lowering therapy, strengthening the Anglo-Swedish drugmaker ...
PMLiVE6d
Merck and Astellas/Pfizer’s bladder cancer combination receives MHRA approval
Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) and Astellas/Pfizer’s Padcev (enfortumab vedotin) have been approved by the Medicines and Healthcare products ...
PMLiVE14d
Results from Global Pharmaceutical Customer Experience survey
Research on the state of the customer experience (CX) that the global pharmaceutical industry provides to healthcare professionals (HCPs) has been released by DT Consulting, an Indegene company. For ...
PMLiVE13d
Chiesi Group invests €400m to establish biotech centre of excellence in Italy
Chiesi Group has announced the operational launch of its biotech centre of excellence in Italy. The company has invested €400m to establish the facility, which it said is dedicated to developing and ...